Roche's Tamiflu successor on target in phase 3 trial

A trial of Roche’s successor to flu medicine Tamiflu has met its goal in a phase 3 trial, with results showing that the new drug Xofluza is well tolerated in children with the flu.

Charity backs R&D into Parkinson's drugs targeting mitochond...

The charity Parkinson’s UK has struck a £1 million partnership with NRG Therapeutics to develop drugs targeted at mitochondria that could protect cells producing dopamine, which have been d

Pfizer’s Revatio flunks paediatric hypertension study

ImmusanT abandons coeliac disease vaccine after phase 2 flop

FDA fast-tracks Lilly/Boehringer’s Jardiance for heart failu...

Oxford Biomedica signs ophthalmology R&D deal with Santen

UK biotech Oxford Biomedica and Japan’s Santen have begun an option and licence agreement to research and develop gene therapy products for an inherited retinal disease.